HOOKIPA Pharma Inc. (HOOK)
NASDAQ: HOOK · Real-Time Price · USD
3.690
-0.150 (-3.91%)
Nov 7, 2024, 4:00 PM EST - Market closed

Company Description

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.

The company’s lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers.

Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial.

The company’s preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus.

HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

HOOKIPA Pharma Inc.
HOOKIPA Pharma logo
Country United States
Founded 2011
IPO Date Apr 18, 2019
Industry Biotechnology
Sector Healthcare
Employees 179
CEO Malte Peters

Contact Details

Address:
350 Fifth Avenue, 72nd Floor
New York, New York 10118
United States
Phone 431 890 6360
Website hookipapharma.com

Stock Details

Ticker Symbol HOOK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $14.00
CIK Code 0001760542
CUSIP Number 43906K100
ISIN Number US43906K1007
Employer ID 81-5395687
SIC Code 2834

Key Executives

Name Position
Dr. Malte Peters M.D. Chief Executive Officer and Director
Mary Theresa Coelho M.B.A. Executive Vice President, Chief Financial Officer and Director
Prof. Rolf M. Zinkernagel M.D., Ph.D. Co-Founder
Andreas Bergthaler Co-Founder
Lukas Flatz Co-Founder
Dr. Roman Necina Ph.D. Chief Operations Officer
Dr. Klaus Orlinger Ph.D. Chief Scientific Officer
Matthew L. S. Beck Executive Director of Investor Relations
Michael Szumera Executive Director of Communications
Dr. Mark Winderlich Ph.D. Chief Research and Development Officer

Latest SEC Filings

Date Type Title
Aug 30, 2024 8-K Current Report
Aug 8, 2024 424B5 Filing
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Aug 2, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jul 26, 2024 8-K Current Report
Jul 10, 2024 8-K Current Report
Jul 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jun 18, 2024 8-K Current Report
Jun 14, 2024 SC 13D General statement of acquisition of beneficial ownership